Cardiff Oncology (CRDF) Free Cash Flow (2011 - 2025)

Cardiff Oncology has reported Free Cash Flow for 15 years, with the latest figure at -$6.0 million in Q4 2025.

• Quarterly Free Cash Flow rose 41.88% year-over-year to -$6.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$38.0 million (down 0.51% YoY) and the FY2025 annual result came in at -$38.0 million, down 0.51% from the prior year.
• Free Cash Flow advanced to -$6.0 million in Q4 2025 per CRDF's latest filing, from -$10.9 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$4.3 million in Q2 2021 and troughed at -$13.7 million in Q1 2025.
• A 5-year average of -$8.2 million and a median of -$7.9 million in 2022 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2022 and 2025: Free Cash Flow slumped 77.09% in 2022, then soared 41.88% in 2025.
• Over 5 years, Free Cash Flow stood at -$7.4 million in 2021, then decreased by 17.51% to -$8.7 million in 2022, then climbed by 17.77% to -$7.1 million in 2023, then sank by 43.65% to -$10.3 million in 2024, then jumped by 41.88% to -$6.0 million in 2025.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$6.0 million, -$10.9 million, and -$7.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.